Novartis CMO John Tsai
October 26, 2020 07:23 AM EDT
R&D

No­var­tis suc­ceeds where Alex­ion failed, com­ing up with a win for a prized as­set in a rare kid­ney dis­or­der

Jason Mast

Editor

Three months af­ter Alex­ion stum­bled, No­var­tis de­clared an­oth­er Phase II suc­cess for a drug it hopes can carve out sig­nif­i­cant new in­di­ca­tions and po­ten­tial­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times